Evidence map›Paper›PMID 41041317›Full record

ArticleFrontiers in immunology2025

Efficacy and safety analysis of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors with or without microwave ablation for unresectable hepatocellular carcinoma: a retrospective, multicenter, case-control study.

Nan Wang, Jingwen Xu, Chengxu Zhan, Pikun Cao, Tianyu Xue, Jinpeng Li, Zhigang Wei, Xin Ye

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nan Wang *Department of First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Jingwen Xu *Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Cardiac Electrophysiology and Arrhythmia, Jinan, China.
Chengxu Zhan *Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Cardiac Electrophysiology and Arrhythmia, Jinan, China.
Pikun CaoDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China.
Tianyu XueDepartment of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Cardiac Electrophysiology and Arrhythmia, Jinan, China.
Jinpeng LiDepartment of Interventional Therapy I, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Zhigang WeiDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China.
Xin YeDepartment of First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) with or without microwave ablation (MWA) for unresectable hepatocellular carcinoma (uHCC). Materials and methods: This retrospective study comprised 220 patients with uHCC who underwent TACE combined with a TKI and ICI with MWA (Group A: 105 patients (median age, 60 ± 10 years) and 82 (78.1%) were men) or without MWA (Group B: 115 patients (median age, 58.35 ± 10.27 years) and 97 (84.4%) were men) at multiple centers in China. The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were compared between the two groups. Results: The OS, PFS, and ORR in Group A were significantly higher than those in Group B (OS, 21.30 ± 8.25 vs. 15.49 ± 7.41 months, Conclusion: The combination therapy (TACE + TKIs and ICIs) with MWA showed higher safety and significantly better OS, PFS, and ORR for uHCC than that without MWA.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticImmune Checkpoint InhibitorsLiver NeoplasmsMicrowavesProtein Kinase InhibitorsAdultAgedCase-Control StudiesCombined Modality TherapyFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsProtein Kinase InhibitorsTyrosine Kinase Inhibitorscombined modality therapyhepatocellular carcinomaimmune checkpoint inhibitorsmicrowave ablationtransarterial chemoembolization

Identifiers

PMID41041317
PMCPMC12484054

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.